Crossmark

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

Crossref DOI link: https://doi.org/10.1038/nnano.2017.69

Published Online: 2017-05-01

Published Print: 2017-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yuan, Hengfeng

Jiang, Wen https://orcid.org/0000-0001-9154-633X
von Roemeling, Christina A.

Qie, Yaqing

Liu, Xiujie

Chen, Yuanxin

Wang, Yifan

Wharen, Robert E.

Yun, Kyuson

Bu, Guojun

Knutson, Keith L.

Kim, Betty Y. S.
License Information

Text and Data Mining valid from 2017-05-01
More Information

Article History

Received: 4 July 2016

Accepted: 15 March 2017

First Online: 1 May 2017

Competing interests

: The Mayo Clinic has filed a patent application on the technology and intellectual property reported here.